Cite

HARVARD Citation

    Hong, D. et al. (n.d.). 285 Phase I clinical trial evaluating the safety of ADP-A2M10 in patients with MAGE-A10+ head and neck, melanoma, or urothelial tumors. Journal for immunotherapy of cancer. p. A174. [Online]. 
  
Back to record